[1] Valent P, Horny HP, Bennett JM, et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference[J]. Leuk Res,2007,31(6):727-736.
[2] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[3] 肖志坚. 正确认识细胞形态学在骨髓增生异常综合征诊断中的地位[J]. 诊断学理论与实践,2013,12(1):1-3.
[4] 肖志坚. 骨髓增生异常综合征的精确诊断[J]. 中华血液学杂志,2015,36(5):361-362.
[5] Feng G, Gale RP, Cui W, et al.A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes[J]. Exp Hematol Oncol,2016,5:12.
[6] Qu S, Xu Z, Zhang Y, et al.Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study[J]. Leuk Lymphoma,2012,53(5):940-946.
[7] 曲士强, 徐泽峰, 李承文, 等. FISH在骨髓增生异常综合征患者细胞遗传学评估中的作用[J]. 中华血液学杂志,2012,33(10):839-842.
[8] 肖志坚. 骨髓增生异常综合征的分子生物学研究:现况与启示[J]. 白血病·淋巴瘤,2014,23(9):513-514.
[9] Wang J, Ai X, Gale RP, et al.TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes[J]. Leuk Res,2013,37(3):305-311.
[10] Cui R, Gale RP, Xu Z, et al.Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts[J]. Leuk Res,2012,36(11):1428-1433. |
